Drug news
CHMP recommends against approval of RLX 030 (serelaxin) for Acute Heart Failure-Novartis
The Committee for Medicinal Products for Human Use (CHMP) recommended against approval for RLX 030(serelaxin) treatment for Acute Heart Failure.
Novartis will file a new application seeking approval to begin marketing the drug on the condition that it undergo another review once a late-stage patient trial begun in September is finished.That is a conditional approval.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.